ClinicalTrials.gov record
No Longer Available No phase listed Expanded access

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

ClinicalTrials.gov ID: NCT04583007

Public ClinicalTrials.gov record NCT04583007. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Study identification

NCT ID
NCT04583007
Recruitment status
No Longer Available
Study type
Expanded access
Phase
Not listed
Lead sponsor
Shire
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

  • Lanadelumab 150 mg Drug
  • Lanadelumab 300 mg Drug

Drug

Eligibility (public fields only)

Age range
2 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Not listed
Last update posted
Jul 23, 2023

United States locations

U.S. sites
14
U.S. states
10
U.S. cities
13
Facility City State ZIP Site status
Medical Research of Arizona Scottsdale Arizona 85251
AIRE Medical of Los Angeles Santa Monica California 90404
Allergy & Asthma Clinical Research Walnut Creek California 94598
Henry J. Kanarek- Allergy, Asthma & Immunology Overland Park Kansas 66211
Institute Asthma and Allergy Chevy Chase Maryland 20815
Institute For Asthma and Allergy Chevy Chase Maryland 20815
University of Michigan Allergy and Immunology Specialty Clinic Ann Arbor Michigan 48109-5008
Hudson-Essex Allergy Belleville New Jersey 07109
Icahn School of Medicine at Mount Sinai New York New York 10029
Clinical Research Center of Charlotte Charlotte North Carolina 28277
Bernstein Clinical Research Center Cincinnati Ohio 45231
Optimed Research, LTD Columbus Ohio 43235
Toledo Institute of Clinical Research Asthma & Allergy Center Toledo Ohio 43617
AARA Research Center Dallas Texas 75231

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04583007, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 23, 2023 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04583007 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →